The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
MicroRNA-33 and the SREBP Host Genes Cooperate to Control Cholesterol Homeostasis
Open accessAbstract
miR-33 in Cholesterol Control: With the well-established link between serum cholesterol levels and cardiovascular disease and the availability of effective cholesterol-lowering drugs, cholesterol screening has rapidly become a routine part of health care. Yet, much remains to be learned about how cholesterol levels are regulated at the cellular level (see the Perspective by Brown et al. ). Now, Najafi-Shoushtari et al. (p. 1566 , published online 13 May) and Rayner et al. (p. 1570 , published online 13 May) have discovered a new molecular player in cholesterol control—a small noncoding RNA that, intriguingly, is embedded within the genes coding for sterol regulatory element-binding proteins (SREBPs), transcription factors already known to regulate cholesterol levels. This microRNA, called miR-33, represses expression of the adenosine triphosphate–binding cassette transporter A1, a protein that regulates synthesis of high-density lipoprotein (HDL, or “good” cholesterol) and that helps to remove “bad” cholesterol from the blood. Reducing the levels of miR-33 in mice boosted serum HDL levels, suggesting that manipulation of this regulatory circuit might be therapeutically useful.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pharmacological inhibition of miR-33 increased plasma high-density lipoprotein cholesterol levels in mice (Horie et al., 2010;Najafi-Shoushtari et al., 2010;Rayner et al., 2011a) and primates (Rayner et al., 2011b;Rottiers et al., 2013), leading to a marked reduction of atherosclerosis phenotypes.”
From microRNA-33 Regulates ApoE Lipidation and Amyloid-β Metabolism in the Brain (2015) · cites this paper as Najafi-Shoushtari et al., 2010
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in vivo antagonism or genetic deletion of miR-33 enhances hepatic ABCA1 expression and increases circulating HDL-cholesterol (HDL-C) (Marquart et al., 2010; Najafi-Shoushtari et al., 2010; Rayner et al., 2010).”
From Genetic dissection of the impact of miR-33a and miR-33b during the progression of atherosclerosis (2017) · cites this paper as Najafi-Shoushtari et al., 2010
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These differences in miRNA expression vary between cell types suggesting that the role of miR-33b in the liver, where miR-33 is most highly expressed both in our mouse model and in human tissues (Najafi-Shoushtari et al., 2010), and other tissues may be considerably more important.”
From Genetic dissection of the impact of miR-33a and miR-33b during the progression of atherosclerosis (2017) · cites this paper as Najafi-Shoushtari et al., 2010
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In miR-33a knockout mice or when miR-33a is suppressed by synthetic nucleic acids such as antagomirs, the expression of ABCA1 in macrophages and the liver is increased 11 - 15) .”
From Critical Role of microRNA-33a/b in Cardiovascular and Metabolic Disease: Molecular Mechanisms and Therapeutic Perspectives (2026) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MicroRNA (miR)-33 is known to target ABCA1 and ABCG1 in vivo.”
From MicroRNA‐33 Deficiency Reduces the Progression of Atherosclerotic Plaque in ApoE −/− Mice (2012) · cites this paper as [17]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two miR-33 genes are present in humans: miR-33b, which is present in intron 17 of the Srebp-1 gene on chromosome 17, and miR-33a, which is located in intron 16 of the Srebp-2 gene on chromosome 22.”
From miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling (2011) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We and others have recently established that, during sterol-limited states, miR-33a is coincidentally generated with Srebp-2 transcription and works to increase cellular cholesterol levels by limiting cholesterol export through the down-regulation of ABC transporters, ABCA1 and ABCG1 (12–14).”
From miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling (2011) · cites this paper as [13]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“miR-33a and miR-33b are intronic miRNAs encoded within the SREBP-2 and SREBP-1 genes respectively (Marquart et al., 2010; Najafi-Shoushtari et al., 2010; Rayner et al., 2010).”
From Genetic dissection of the impact of miR-33a and miR-33b during the progression of atherosclerosis (2017) · cites this paper as Najafi-Shoushtari et al., 2010
The cited source says what the claim attributes to it.
In the citing paper
“This work led to the demonstration that miR-33a and miR-33b are co-transcribed along with SREBP-2 and SREBP-1, and work in concert with their host genes to help maintain proper lipid levels within the cell (Davalos et al., 2011; Marquart et al., 2010; Najafi-Shoushtari et al., 2010; Rayner et al., 2010).”
From Genetic dissection of the impact of miR-33a and miR-33b during the progression of atherosclerosis (2017) · cites this paper as Najafi-Shoushtari et al., 2010
The cited source says what the claim attributes to it.
In the citing paper
“The most well-known target gene of miR-33a/b is ATP-binding cassette subfamily A member 1 (ABCA1).”
From Critical Role of microRNA-33a/b in Cardiovascular and Metabolic Disease: Molecular Mechanisms and Therapeutic Perspectives (2026) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“Recent reports, including ours, have indicated that miR-33 controls cholesterol homeostasis based on knockdown experiments using antisense technology.16–18”
From MicroRNA‐33 Deficiency Reduces the Progression of Atherosclerotic Plaque in ApoE −/− Mice (2012) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“We and others provided identification of a highly conserved miRNA family, miR-33, within the intronic sequences of the Srebp genes in organisms ranging from Drosophila to humans (11–14).”
From miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling (2011) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“In mice, however, there is only one miR-33 gene, which is conserved with human miR-33a and located within intron 15 of the mouse Srebp-2 gene.”
From miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling (2011) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“Importantly, these pathways regulate circulating HDL levels through their roles in HDL biogenesis and cellular cholesterol efflux (12–14).”
From miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling (2011) · cites this paper as [13]
In the citing paper
“These microRNAs participate in the regulation of cholesterol synthesis, fatty acid metabolism, and insulin signaling.”
From The Vasculature in Prediabetes (2018) · cites this paper as [143]
In the citing paper
“They are co-transcribed and act in conjunction with their host genes, Srebp1 and Srebp2, to regulate cholesterol synthesis.”
From The Vasculature in Prediabetes (2018) · cites this paper as [143]
In the citing paper
“Furthermore, an intronic microRNA located within Srebf2 gene, miR-33, inhibits the expression of Abca1 (Najafi-Shoushtari et al., 2010; Rayner et al., 2010).”
From Inhibition of cholesterol biosynthesis through RNF145-dependent ubiquitination of SCAP (2017) · cites this paper as Najafi-Shoushtari et al., 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
MicroRNAs: Target Recognition and Regulatory Functions
Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.01.002 · Cited by 20,068
MicroRNAs: small RNAs with a big role in gene regulation
He, L., & Hannon, G. J. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1379 · Cited by 7,118
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
Brown, M. S., & Goldstein, J. L. (1997) · Cell · doi:10.1016/s0092-8674(00)80213-5 · Cited by 3,834
Identification of Mammalian microRNA Host Genes and Transcription Units
Rodriguez, A., Griffiths-Jones, S., Ashurst, J. L., & Bradley, A. (2004) · Genome Research · doi:10.1101/gr.2722704 · Cited by 2,128
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
Esau, C., Davis, S., Murray, S. F., Yu, X. X., Pandey, S. K., Pear, M., Watts, L., Booten, S. L., Graham, M., McKay, R., et al. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.005 · Cited by 2,082
LNA-mediated microRNA silencing in non-human primates
Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjärn, M., Hansen, H. F., Berger, U., et al. (2008) · Nature · doi:10.1038/nature06783 · Cited by 1,589
Research works printed but not linked: 1
- 10.1172/jci0215748 · DOI · Paper page
Cited by
Sorted by citations
Items 501–600 of 957
Walker, A. K., & Näär, A. M. (2012) · Clinical Lipidology · doi:10.2217/clp.11.67 · Cited by 25
Self-citationSud, N., Taher, J., & Su, Q. (2015) · Drug Development Research · doi:10.1002/ddr.21269 · Cited by 25
Aberrant expression of plasma microRNA-33a in an atherosclerosis-risk group
Kim, S. H., Kim, G. J., Umemura, T., Lee, S. G., & Cho, K. J. (2016) · Molecular Biology Reports · doi:10.1007/s11033-016-4082-z · Cited by 24
Refeat, M. M., Hassan, N. A.-M., Ahmad, I. H., Mostafa, E. R. M., & Amr, K. S. (2021) · Journal of Genetic Engineering and Biotechnology · doi:10.1186/s43141-021-00246-8 · Cited by 25
Inflammatory microRNAs in cardiovascular pathology: another brick in the wall
Zapata-Martínez, L., Águila, S., Reyes‐García, A. M. D. L., Carrillo‐Tornel, S., Lozano, M. L., Gónzález‐Conejero, R., & Martínez, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1196104 · Cited by 26
MicroRNAs as a Potential Biomarker in the Diagnosis of Cardiovascular Diseases
Kramna, D., Riedlová, P., & Jiřík, V. (2023) · Medicina · doi:10.3390/medicina59071329 · Cited by 19
“Micromanaging” metabolic syndrome
Ramírez, C. M., Goedeke, L., & Fernandez-Hernando, C. F. (2011) · Cell Cycle · doi:10.4161/cc.10.19.17558 · Cited by 24
MicroRNA-34a and Impaired FGF19/21 Signaling in Obesity
Fu, T., & Kemper, J. K. (2016) · Vitamins and hormones · doi:10.1016/bs.vh.2016.02.002 · Cited by 24
MicroRNAs in Ischemic Heart Disease
Lima, J., Batty, J. A., Sinclair, H., & Kunadian, V. (2016) · Cardiology in Review · doi:10.1097/crd.0000000000000114 · Cited by 24
Li, Y., Sun, Y., Hao, R., Pin, W., Zhang, L., Ma, X., Ma, Y., Wang, P., Xie, N., Xie, S., et al. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4276 · Cited by 24
Self-citationRole of Noncoding RNA in Development of Nonalcoholic Fatty Liver Disease
Huang, R. X., Duan, X., Fan, J., Li, G., & Wang, B. (2019) · BioMed Research International · doi:10.1155/2019/8690592 · Cited by 24
Systematic exploration of cancer‐associated microRNA through functional screening assays
Izumiya, M., Tsuchiya, N., Okamoto, K., & Nakagama, H. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02007.x · Cited by 24
MicroRNAs in brain cholesterol metabolism and their implications for Alzheimer's disease
Yoon, H., Flores, L. F., & Kim, J. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.04.020 · Cited by 23
Saponins as therapeutic candidates for atherosclerosis
Lv, N., Wang, L., Zeng, M., Wang, Y., Yu, B., Zeng, W., Jiang, X., & Suo, Y. (2024) · Phytotherapy Research · doi:10.1002/ptr.8128 · Cited by 23
MicroRNAs and High-Density Lipoprotein Cholesterol Metabolism
Ono, K., Horie, T., Nishino, T., Baba, O., Kuwabara, Y., & Kimura, T. (2015) · International Heart Journal · doi:10.1536/ihj.15-019 · Cited by 24
Cardiovascular inflammation: RNA takes the lead
Martens, C. R., Bansal, S. S., & Accornero, F. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.03.012 · Cited by 23
Hicks, J. A., Porter, T. E., Sunny, N. E., & Liu, H. (2019) · Genes · doi:10.3390/genes10040272 · Cited by 23
Koyama, S., Horie, T., Nishino, T., Baba, O., Sowa, N., Miyasaka, Y., Kuwabara, Y., Nakao, T., Nishiga, M., Nishi, H., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012609 · Cited by 23
Exploring the regulatory roles of circular RNAs in the pathogenesis of atherosclerosis
Sun, X., Deng, K., Zang, Y., Zhang, Z., Zhao, B., Fan, J., & Huang, L. (2021) · Vascular Pharmacology · doi:10.1016/j.vph.2021.106898 · Cited by 21
Connecting the dots in the associations between diet, obesity, cancer, and microRNAs
Otsuka, K., Nishiyama, H., Kuriki, D., Kawada, N., & Ochiya, T. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.05.001 · Cited by 26
MicroRNAs mediate metabolic stresses and angiogenesis
Patella, F., & Rainaldi, G. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0775-6 · Cited by 23
Ohoka, N., Okuhira, K., Cui, H., Wu, W., Sato, R., Naito, M., & Nishimaki‐Mogami, T. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.238360 · Cited by 23
Strategies to Antagonize miRNA Functions In Vitro and In Vivo
Baigude, H., & Rana, T. M. (2014) · Nanomedicine · doi:10.2217/nnm.14.162 · Cited by 23
Zambrano, T., Hirata, R. D. C., Hirata, M. H., Cerda, Á., & Salazar, L. A. (2015) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-015-6627-0 · Cited by 23
Zhu, T., Corraze, G. R., Plagnes‐Juan, E., & Cassy, S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0223813 · Cited by 27
Targeting miRNA by Natural Products: A Novel Therapeutic Approach for Nonalcoholic Fatty Liver
Zobeiri, M., Parvizi, F., Kalhori, M. R., Majnooni, M. B., Farzaei, M. H., & Abdollahi, M. R. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/6641031 · Cited by 22
Potential Therapeutic Agents That Target ATP Binding Cassette A1 (ABCA1) Gene Expression
Haas, M. J., & Mooradian, A. D. (2022) · Drugs · doi:10.1007/s40265-022-01743-x · Cited by 23
Discovery of Novel and Differentially Expressed MicroRNAs between Fetal and Adult Backfat in Cattle
Sun, J., Zhou, Y., Cai, H., Lan, X., Lei, C., Zhao, X., Zhang, C., & Chen, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090244 · Cited by 22
Plasma microRNA markers of upper limb recovery following human stroke
Edwardson, M. A., Zhong, X., Fiandaca, M. S., Federoff, H. J., Cheema, A. K., & Dromerick, A. W. (2018) · Scientific Reports · doi:10.1038/s41598-018-31020-5 · Cited by 22
van Ingen, E., Foks, A. C., Kröner, M. J., Kuiper, J., Quax, P. H. A., Bot, I., & Nossent, A. Y. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.09.021 · Cited by 21
Cholesterol in Pancreatic β-Cell Death and Dysfunction
Paul, R. K., Choudhury, A., Choudhury, S., Mazumder, M. K., & Borah, A. (2015) · Pancreas · doi:10.1097/mpa.0000000000000486 · Cited by 22
miR-33 deletion in hepatocytes attenuates MASLD-MASH-HCC progression
Fernández-Tussy, P., Cardelo, M. P., Zhang, H., Sun, J., Price, N. L., Boutagy, N. E., Goedeke, L., Cadena-Sandoval, M., Xirouchaki, C. E., Brown, W., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.168476 · Cited by 21
“…from our group and others identified miR-33 as an intronic miRNA hosted within the sterol regulatory element-binding protein 2 ( SREBF2 ) gene (33–35). miR-33 plays a pivotal role in metabolism through the regulation of mRNA transcripts involved in a wide variety of metabolic processes,…”
BackgroundGanjali, S., Momtazi‐Borojeni, A. A., Banach, M., Kovanen, P. T., Gotto, A. M., & Sahebkar, A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.09.014 · Cited by 21
Xie, R.-T., Cong, X.-L., Zhong, X., Luo, P., Yang, H., Lu, G., Luo, P., Chang, Z.-Y., Sun, R., Wu, T.-M., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.7892 · Cited by 21
Small Molecules with Big Impacts on Cardiovascular Diseases
Azad, F. M., Arabian, M., Maleki, M., & Malakootian, M. (2020) · Biochemical Genetics · doi:10.1007/s10528-020-09948-z · Cited by 21
Role of non-coding RNAs on liver metabolism and NAFLD pathogenesis
Qian, G., & Morral, N. (2022) · Human Molecular Genetics · doi:10.1093/hmg/ddac088 · Cited by 21
A big role for small RNAs in HDL homeostasis
Ouimet, M. I., & Moore, K. J. (2013) · Journal of Lipid Research · doi:10.1194/jlr.r036327 · Cited by 21
Recent Advances in Understanding of NASH: MicroRNAs as Both Biochemical Markers and Players
Vincent, R. J., & Sanyal, A. J. (2014) · Current Pathobiology Reports · doi:10.1007/s40139-014-0049-8 · Cited by 21
Micro RNA-19a suppresses IL-10 in peripheral B cells from patients with atherosclerosis
Ren, Z.-Q., Liu, N., & Zhao, K. (2016) · Cytokine · doi:10.1016/j.cyto.2016.07.019 · Cited by 21
Chen, C., Zhang, J., Zhang, M., You, C., Liu, Y., Wang, S., & Li, Y. (2018) · Gene · doi:10.1016/j.gene.2018.08.063 · Cited by 21
Self-citationFunctional Regulation of Macrophage Phenotypes by MicroRNAs in Inflammatory Arthritis
Niu, X., & Schulert, G. S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02217 · Cited by 23
MicroRNA-33 Inhibits Adaptive Thermogenesis and Adipose Tissue Beiging
Afonso, M. S., Verma, N., van Solingen, C., Cyr, Y., Sharma, M., Perie, L., Corr, E. M., Schlegel, M., Shanley, L. C., Peled, D., et al. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.120.315798 · Cited by 21
Targeting of miR-33 ameliorates phenotypes linked to age-related macular degeneration
Gnanaguru, G., Wagschal, A., Oh, J. D., Saez‐Torres, K. L., Li, T., Temel, R. E., Kleinman, M. E., Näär, A. M., & D'Amore, P. A. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.03.014 · Cited by 21
Self-citationMOVAS Cells: A Versatile Cell Line for Studying Vascular Smooth Muscle Cell Cholesterol Metabolism
Esobi, I. C., Barksdale, C., Heard‐Tate, C., Powell, R. R., Bruce, T. F., & Stamatikos, A. (2021) · Lipids · doi:10.1002/lipd.12303 · Cited by 23
Igf2-derived intronic miR-483 promotes mouse hepatocellular carcinoma cell proliferation
Ma, N., Li, F., Li, D., Hui, Y., Wang, X., Qiao, Y., Zhang, Y., Xiang, Y., Zhou, J., Zhou, L., et al. (2011) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-011-1121-x · Cited by 20
Behavioral stress reduces RIP140 expression in astrocyte and increases brain lipid accumulation
Feng, X., Lin, Y., & Wei, L. (2015) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2015.02.008 · Cited by 20
Intronic miR-932 targets the coding region of its host gene, Drosophila neuroligin2
Qian, J., Tu, R., Yuan, L., & Xie, W. (2016) · Experimental Cell Research · doi:10.1016/j.yexcr.2016.01.017 · Cited by 20
Ogasawara, F., & Ueda, K. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102702 · Cited by 20
Pivotal role of microRNA-33 in metabolic syndrome: A systematic review.
Gharipour, M., & Sadeghi, M. (2013) · Europe PMC (PubMed Central) · Cited by 20
Zhou, J., Meng, Y., Tian, S., Chen, J., Liu, M., Zhuo, M., Zhang, Y., Du, H., & Wang, X. (2014) · Journal of Diabetes Research · doi:10.1155/2014/760397 · Cited by 21
Coleman, E. M., Walker, T. N., & Hildreth, J. E. K. (2012) · Virology Journal · doi:10.1186/1743-422x-9-31 · Cited by 20
Sun, J. J., Zheng, L. G., Chen, C. Y., Zhang, J. Y., You, C., Zhang, Q. H., Yu, H., Monroig, Ó., Tocher, D. R., Wang, S. Q., et al. (2019) · Marine Biotechnology · doi:10.1007/s10126-019-09895-w · Cited by 20
Self-citationLightbody, R. J., Taylor, J. M. W., Dempsie, Y., & Graham, A. (2020) · World Journal of Cardiology · doi:10.4330/wjc.v12.i7.303 · Cited by 20
Implications for MicroRNA involvement in the prognosis and treatment of atherosclerosis
Tabaei, S., & Tabaee, S. S. (2021) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-020-03992-4 · Cited by 21
Novel Role of miR-33 in Regulating of Mitochondrial Function
Price, N. L., & Fernandez-Hernando, C. F. (2015) · Circulation Research · doi:10.1161/circresaha.117.306949 · Cited by 19
Vickers, K. C., & Moore, K. J. (2013) · Circulation Research · doi:10.1161/circresaha.113.302732 · Cited by 20
Regulatory T cells and macrophages in atherosclerosis: from mechanisms to clinical significance
Ouyang, X., & Liu, Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1435021 · Cited by 20
Katsube, A., Hayashi, H., & Kusuhara, H. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.308472 · Cited by 19
Tao, Y., Xu, S., Wang, J., Xu, L., Zhang, C., Chen, K., Lian, Z., Zhou, J., Xie, H., Zheng, S., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00921 · Cited by 20
Helicoverpa armigera miR-2055 regulates lipid metabolism via fatty acid synthase expression
Yang, C., Lu, T., Guo, J., et al. (2022) · Open Biology · doi:10.1098/rsob.210307 · Cited by 19
Sum, H., & Brewer, A. C. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1183181 · Cited by 20
miR-28-5p Involved in LXR-ABCA1 Pathway is Increased in the Plasma of Unstable Angina Patients.
Liu, J., Liu, Y., Sun, Y.-N., Li, S., Liu, X.-Q., Li, J., Li, C.-M., Tian, W., Zhou, Y.-T., & Shang, X.-M. (2015) · Heart, Lung and Circulation · doi:10.1016/j.hlc.2014.12.160 · Cited by 19
MicroRNAs and Cardiovascular Disease
Fernandez-Hernando, C. F., & Baldán, Á. (2013) · Current Genetic Medicine Reports · doi:10.1007/s40142-013-0008-4 · Cited by 19
Hung, Y.-H., Kanke, M., Kurtz, C. L., Cubitt, R. L., Bunaciu, R. P., Zhou, L., White, P. J., Vickers, K. C., Hussain, M. M., Li, X., et al. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.01367 · Cited by 19
Pagano, S., Magenta, A., D'Agostino, M., Martino, F., Barillà, F., Satta, N., Frias, M. A., Ronca, A., Mach, F., Gencer, B., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122035 · Cited by 22
MiR‐22 modulates the expression of lipogenesis‐related genes and promotes hepatic steatosis in vitro
Yang, Z., Qin, W., Huo, J., Zhuo, Q., Wang, J., & Wang, L. (2020) · FEBS Open Bio · doi:10.1002/2211-5463.13026 · Cited by 19
Detection of miR-33 Expression and the Verification of Its Target Genes in the Fatty Liver of Geese
Zheng, Y., Jiang, S., Zhang, Y., Zhang, R., & Gong, D. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160612737 · Cited by 19
MicroRNA-Management of Lipoprotein Homeostasis
Sun, X., & Feinberg, M. W. (2014) · Circulation Research · doi:10.1161/circresaha.114.304228 · Cited by 19
The power of microRNA regulation—insights into immunity and metabolism
Oliveto, S., Manfrini, N., & Biffo, S. (2025) · FEBS Letters · doi:10.1002/1873-3468.70039 · Cited by 21
Liu, F., Gong, R., Lv, X., et al. (2018) · Gene · doi:10.1016/j.gene.2018.01.089 · Cited by 18
microRNAs involved in psoriasis and cardiovascular diseases
Sileno, S., Beji, S., D'Agostino, M., Carassiti, A., Melillo, G., & Magenta, A. (2021) · Vascular Biology · doi:10.1530/vb-21-0007 · Cited by 17
Peng, C., Pan, L., Li, X., et al. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1125-1 · Cited by 18
Metformin reduces lipid accumulation in HepG2 cells via downregulation of miR-33b
Zare, M., Panahi, G., Koushki, M., Mostafavi‐Pour, Z., & Meshkani, R. (2019) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2019.1680700 · Cited by 18
Signal Transduction and Molecular Regulation in Fatty Liver Disease
Dong, X. C., Chowdhury, K., Huang, M., & Kim, H.-G. (2021) · Antioxidants and Redox Signaling · doi:10.1089/ars.2021.0076 · Cited by 18
Cerda, Á., Hirata, M. H., & Hirata, R. D. C. (2012) · Drug metabolism and drug interactions · doi:10.1515/dmdi-2012-0007 · Cited by 19
MicroRNA-101-2-5p targets the ApoB gene in the liver of chicken (Gallus Gallus)
Ma, Z., Li, H., Zheng, H., Jiang, K., Jia, L., Yan, F., Tian, Y., Kang, X., Wang, Y., & Liu, X. (2017) · Genome · doi:10.1139/gen-2017-0020 · Cited by 18
The MicroRNA Interaction Network of Lipid Diseases
Kandhro, A. H., Shoombuatong, W., Nantasenamat, C., Prachayasittikul, V., & Nuchnoi, P. (2017) · Frontiers in Genetics · doi:10.3389/fgene.2017.00116 · Cited by 17
Song, M., Xu, S., Zhong, A., & Zhang, J. (2019) · Clinical Immunology · doi:10.1016/j.clim.2019.03.001 · Cited by 18
An update on the roles of immune system-derived microRNAs in cardiovascular diseases
Roberts, L. B., Kapoor, P., Howard, J. K., Shah, A. M., & Lord, G. M. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab007 · Cited by 18
Ebrahimi, M. M., Rajion, M. A., Meng, G. Y., et al. (2014) · BioMed Research International · doi:10.1155/2014/749341 · Cited by 17
Therapeutic gene targeting approaches for the treatment of dyslipidemias and atherosclerosis
Mäkinen, P. I., & Ylä‐Herttuala, S. (2013) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32835da13c · Cited by 17
Harnessing the Therapeutic Potential of MicroRNAs for Cardiovascular Disease
Calway, T., & Kim, G. H. (2014) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248414552902 · Cited by 17
Lin, J., Maimaitiyiming, A., Chen, S., Xiao, M., & Xian, Z. (2021) · Aging · doi:10.18632/aging.202778 · Cited by 17
Reverse Cholesterol Transport Dysfunction Is a Feature of Familial Hypercholesterolemia
Escolá‐Gil, J. C., Rotllán, N., Julve, J., & Blanco‐Vaca, F. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00928-1 · Cited by 17
A genome-wide survey for prion-regulated miRNAs associated with cholesterol homeostasis
Montag, J., Brameier, M., Schmädicke, A.-C., Gilch, S., Schätzl, H. M., & Motzkus, D. (2012) · BMC Genomics · doi:10.1186/1471-2164-13-486 · Cited by 18
Update on HDL Receptors and Cellular Cholesterol Transport
Kellner-Weibel, G., & de la Llera-Moya, M. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0169-0 · Cited by 17
miRNAs and High-Density Lipoprotein metabolism
Baldán, Á., & Vallim, T. Q. D. A. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.01.021 · Cited by 18
MicroRNA-33 suppresses CCL2 expression in chondrocytes
Wei, M., Xie, Q.-Y., Zhu, J., Wang, T., Zhang, F., Cheng, Y., Guo, D.-Y., Wang, Y., Mo, L.-W., & Wang, S. (2016) · Bioscience Reports · doi:10.1042/bsr20160068 · Cited by 18
Development of Antisense Drugs for Dyslipidemia
Yamamoto, T., Wada, F., & Harada‐Shiba, M. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv16001 · Cited by 17
Deng, X., Qin, S., Chen, Y., Liu, H.-Y., Yuan, E., Deng, H., & Liu, S. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.03.024 · Cited by 17
Hepatocyte miR‐33a mediates mitochondrial dysfunction and hepatosteatosis by suppressing NDUFA5
Nie, H., Yu, X.-H., He, H.-H., Zhou, L., Li, Q., Song, C.-L., Wang, D.-M., Ren, T., Chen, Z., Huang, H., et al. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13918 · Cited by 17
Collura, S., Morsiani, C., Vacirca, A., Fronterrè, S., Ciavarella, C., Vasuri, F., D’Errico, A., Franceschi, C., Pasquinelli, G., Gargiulo, M., et al. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101090 · Cited by 17
Anti-atherosclerosis or No Anti-atherosclerosis
Näär, A. M. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.301021 · Cited by 17
Self-citationMicroRNAs and Nonalcoholic Steatohepatitis: A Review
Morishita, A., Oura, K., Tadokoro, T., Fujita, K., Tani, J., Kobara, H., Ono, M., Himoto, T., & Masaki, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914482 · Cited by 19
Cerrato, F., Fernández‐Suárez, M. E., Rodrigo Alonso, K., Alonso, M. E., Vázquez, C., Pastor, Ó., Mata, P., Lasunción, M. A., & Gómez‐Coronado, D. (2014) · British Journal of Pharmacology · doi:10.1111/bph.13016 · Cited by 17
Chen, T., Yan, D., Cheng, X., Ji, X., Bian, J., & Yin, W. (2018) · Endocrinology · doi:10.1210/en.2017-03231 · Cited by 16
Wu, H., Fan, F., Liang, C., et al. (2019) · Animal Reproduction Science · doi:10.1016/j.anireprosci.2019.01.002 · Cited by 16
From Endothelium to Lipids, Through microRNAs and PCSK9: A Fascinating Travel Across Atherosclerosis
D’Ardes, D., Santilli, F., Guagnano, M. T., Bucci, M., & Cipollone, F. (2020) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-019-00356-y · Cited by 17
Comparative microRNA Transcriptomes in Domestic Goats Reveal Acclimatization to High Altitude
Feng, S., Ma, J., Long, K., Zhang, J., Qiu, W., Li, Y., Jin, L. G., Wang, X., Jiang, A., Liu, L., et al. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00809 · Cited by 16
Self-citationMicroRNA in cardio-metabolic disorders
Su, X., Nie, M., Zhang, G., & Wang, B. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.03.024 · Cited by 18
Metadata
- Authors
- Najafi-Shoushtari, S. H., Kristo, F., Li, Y., Shioda, T., Cohen, D. E., Gerszten, R. E., & Näär, A. M.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Näär, Anders M.
- ORCID
- Venue
- Science
- Published
- 2010-06-18
- Volume
- 328
- Issue
- 5985
- Pages
- 1566-1569
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3840500
- OpenAlex
- W2102901373
- Semantic Scholar
- 8e1f87e5a8c468d11cb938b52c20c8e6954402ce
- Cited by
- 957
- References
- 31
- Citations by year
- 2026: 20 · 2025: 30 · 2024: 24 · 2023: 47 · 2022: 41 · 2021: 56 · 2020: 50 · 2019: 65 · 2018: 66 · 2017: 59 · 2016: 86 · 2015: 88 · 2014: 85 · 2013: 92 · 2012: 73
- FWCI
- 80.88
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of General Medical Sciences (R01GM071449)
- National Institute of Diabetes and Digestive and Kidney Diseases (R21DK084459, R01 DK48873, P30-DK34854, R01DK056626, R01 DK56626, R37DK048873, P30DK034854, R01DK048873)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- miR-33, cholesterol homeostasis, ABCA1, reverse cholesterol transport, HDL synthesis, cholesterol efflux, post-transcriptional regulation, antisense oligonucleotides, locked nucleic acid, cholesterol biosynthesis, cardiometabolic disease
- MeSH terms
- Animals, Cell Line, Cholesterol, Diet, Gene Expression Regulation, Homeostasis, Humans, Introns, Cholesterol, HDL, Liver, Macrophages, Mice, Inbred C57BL, Up-Regulation, Oligonucleotides, Antisense, ATP-Binding Cassette Transporters, 3' Untranslated Regions, RNA Interference, MicroRNAs, Mice, Sterol Regulatory Element Binding Proteins, Sterol Regulatory Element Binding Protein 1, Sterol Regulatory Element Binding Protein 2, ATP Binding Cassette Transporter 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
